Table 1.
PD model parameters of AUCcum‒SPD relationship in patients with relapsed/refractory NHL.
| All Patients (N = 68)a | ||||||
|---|---|---|---|---|---|---|
| Eo | Emax | Eo‒Emax | EC50 | ɣ | AUCcum at 0.5-fold SPD Change | |
| Parameter estimate | 1.20-fold (20% increase) |
1.15 | 0.05-fold (95% decrease) |
1,000 h×µg/L | 1.50 | 1,340 h×µg/L |
| CV% | 13% | 32% | ‒ | 45% | 60% | ‒ |
AUCcum cumulative area under the concentration-versus-time curve, Css concentration at steady state, EC50 median effective concentration, ɣ sigmoidicity factor, Emax maximum decrease in SPD relative to Eo, Eo baseline change in SPD from screening prior to blinatumomab treatment, NHL non-Hodgkin lymphoma, PD pharmacodynamics, SPD sum of the products of the largest diameters. CV% reflects accuracy in parameter estimates. aAll patients with evaluable samples.